Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.50 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | JUN | P05412 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10379177 | 0.87 | CYP1A2 (0.55) | MAPTLMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4924923 | 0.86 | CYP3A4 (0.69) | MAPTLMNATRIM24TRIM33CYP1A2 | |
| SCHEMBL4924930 | 0.86 | CYP3A4 (0.69) | MAPTLMNATRIM24TRIM33CYP1A2 | |
| SCHEMBL29833552 | 0.86 | CYP3A4 (0.69) | MAPTLMNATRIM24TRIM33CYP1A2 | |
| SCHEMBL15271482 | 0.83 | MAPT (0.55) | MAPTLMNATRIM24TRIM33NFKB1 | |
| SCHEMBL17122440 | 0.83 | MAPT (0.55) | MAPTLMNATRIM24TRIM33NFKB1 | |
| SCHEMBL15271480 | 0.83 | MAPT (0.55) | MAPTLMNATRIM24TRIM33NFKB1 | |
| SCHEMBL4926161 | 0.82 | MAPT (0.58) | MAPTLMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4926158 | 0.82 | MAPT (0.58) | MAPTLMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL7607193 | 0.81 | NFKB1 (0.53) | MAPTLMNATRIM24TRIM33ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080305066-A1 | 2-C-Substituted Propane-1,3-Dicarbonyl Compounds and Their Use in Neutralising Malodour | GIVAUDAN SA (CH) | 2008-12-11 | — | — | US | claimed |
| US-20240041752-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2024-02-08 | — | — | US | disclosed |
| EP-4288022-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan SA (CH) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022167123-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2022-08-11 | — | — | WO | disclosed |
| EP-4039244-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan SA (CH) | 2022-08-10 | — | — | EP | disclosed |
| US-20080305066-A1 | 2-C-Substituted Propane-1,3-Dicarbonyl Compounds and Their Use in Neutralising Malodour | GIVAUDAN SA (CH) | 2008-12-11 | — | — | US | disclosed |
| EP-1838278-A1 | 2-C-SUBSTITUTED PROPANE-1,3-DICARBONYL COMPOUNDS AND THEIR USE IN NEUTRALISING MALODOUR | Givaudan SA (CH) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006076821-A1 | 2 -C-SUBSTITUTED PROPANE-1, 3 -DICARBONYL COMPOUNDS AND THEIR USE IN NEUTRALISING MALODOUR | GIVAUDAN SA (CH) | 2006-07-27 | — | — | WO | disclosed |
| EP-0440324-B1 | Substituted beta-diketones and their use in the treatment of inflammatory bowel disease | ORION YHTYMAE OY (FI) | 2000-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305066-A1 | 2-C-Substituted Propane-1,3-Dicarbonyl Compounds and Their Use in Neutralising Malodour | TYR, MAL2, ACMSD | MAPT 3095/4885LMNA 2738/4885TRIM24 3165/4885 |
| US-20240041752-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | AOX1, TYR, OCIAD1 | MAPT 2293/4885LMNA 3936/4885TRIM24 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.